Сравнение
LL-37 vs. Teduglutid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
597562-32-8
197922-42-2
Молекулярная масса
4493.33 g/mol
3752.13 g/mol
Период полувыведения
нет данных
нет данных
Последовательность
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESнет данных
Механизм действия
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Доказательная база
Наивысшая доказательность
Исследование на людях
РКИ на людях
Исследования
4
2
из них на людях
1
2
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
0
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between LL-37 and Teduglutid?
- LL-37 is classified as "Исследования (прочее)", while Teduglutid is classified as "Исследования (прочее)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Teduglutid?
- The highest available evidence level is "Исследование на людях" for LL-37 and "РКИ на людях" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Teduglutid in Germany and the United States?
- Германия: LL-37 — Только для исследований, Teduglutid — Рецептурный. США: LL-37 — Только для исследований, Teduglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.